MSD secures victory before English court

The English High Court has concluded that Merck Sharp Dohme (MSD) is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Wyeth secures Australian injunction against MSD vaccine

30 November 2020 The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.

Asia-Pacific

Australian court issues mixed vaccine patent ruling

15 October 2020 In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.

Americas

Appeals court sides with Pfizer, Merck KGaA in $5bn suit

29 September 2020 The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

MSD secures victory before English court

More on this story

Editor's picks

Editor's picks

More features